# Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis

> **NCT02128542** · PHASE4 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 66 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** Sofosbuvir
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT02128542
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2016-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02128542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02128542, "Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02128542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*